Answers are grounded in this paper and cite their sources.
This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.
No takes yet. Share an insight, caveat, or question.
Yazdany et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: